摘要
<span style="font-family:Verdana;">Immense changes have been introduced in psoriasis treatment, including</span><span><span><span style="font-family:""><span style="font-family:Verdana;"> suc</span><span style="font-family:Verdana;">cessful systemic treatment of inflammation and education of psoriatic pa</span><span style="font-family:Verdana;">tients. The focus of this review </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">is</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> the latest developments in the understanding of the aetiopathogenesis of psoriasis, the significance of its comorbidities, treatment possibilities and long-term management using the latest insight provided by pharmacogenetics and identification of biomarkers. The successful control of the disease leads to reduction of myocardial infarction and long-term cardiovascular risk but is usually achieved after various therapeutic attempts until the best-matched treatment for the individual is identified. There is a high unmet medical need for revealing biomarkers associated with disease prognosis, comorbidities, response to therapy and adverse effects. More studies have to be performed for identification and validation of biomarkers and implementation of personalized medicine into clinical practice.</span></span></span>
<span style="font-family:Verdana;">Immense changes have been introduced in psoriasis treatment, including</span><span><span><span style="font-family:""><span style="font-family:Verdana;"> suc</span><span style="font-family:Verdana;">cessful systemic treatment of inflammation and education of psoriatic pa</span><span style="font-family:Verdana;">tients. The focus of this review </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">is</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> the latest developments in the understanding of the aetiopathogenesis of psoriasis, the significance of its comorbidities, treatment possibilities and long-term management using the latest insight provided by pharmacogenetics and identification of biomarkers. The successful control of the disease leads to reduction of myocardial infarction and long-term cardiovascular risk but is usually achieved after various therapeutic attempts until the best-matched treatment for the individual is identified. There is a high unmet medical need for revealing biomarkers associated with disease prognosis, comorbidities, response to therapy and adverse effects. More studies have to be performed for identification and validation of biomarkers and implementation of personalized medicine into clinical practice.</span></span></span>
作者
Tanja Gmeiner
Jasna Grzelj
Borut Strukelj
Luka Stopar
Pij Bogomir Marko
Tanja Gmeiner;Jasna Grzelj;Borut Strukelj;Luka Stopar;Pij Bogomir Marko(Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia;Krka, d. d., Novo Mesto, Slovenia;Institute Jozef Stefan, Ljubljana, Slovenia;Department of Dermatovenerology, University Medical Centre Maribor, Maribor, Slovenia)
